암 지지요법 약제 시장 : 치료군별, 용도별 - 세계 전망(2025-2030년)

The Cancer Supportive Care Drugs Market was valued at USD 20.62 billion in 2023, expected to reach USD 21.46 billion in 2024, and is projected to grow at a CAGR of 4.50%, to USD 28.06 billion by 2030.

Cancer supportive care drugs are crucial in oncology, providing relief from treatment-related side effects and enhancing patients' quality of life during cancer therapies. This market encompasses a wide range of medications, including antiemetics, hematopoietic growth factors, bisphosphonates, and analgesics, aimed at managing symptoms like nausea, anemia, and bone pain commonly associated with cancer treatments. The growing prevalence of cancer worldwide and advancements in chemotherapy and radiation therapies underscore the necessity for these supportive drugs. The application of these drugs spans across various oncology departments and is primarily utilized by hospitals, cancer centers, and outpatient facilities, where they support not only adult patients but pediatric cases as well.

Key growth influencers include the increasing investment in oncology research, the rising demand for personalized medicine, and the focus on improving patient care standards. Additionally, the market is witnessing potential opportunities driven by innovations such as targeted supportive care solutions and the integration of digital health tools to manage symptoms and medication adherence more effectively. Rapid technological advancements and a collaborative approach between pharmaceutical companies and healthcare providers offer strategic opportunities to capitalize on the evolving needs of cancer care. Meanwhile, limitations such as high treatment costs, regulatory hurdles, and the variable efficacy of supportive drugs pose challenges to market expansion. Moreover, the competitive landscape can be stringent, requiring constant innovation to meet emerging patient needs and regulatory standards.

Areas ripe for innovation and research include the development of novel drug delivery mechanisms, exploration of biosimilars to reduce costs, and investigation into complementary and alternative therapies. The nature of the market is dynamic and heavily reliant on emerging scientific evidence and technology, emphasizing the need for comprehensive market strategies and collaboration with healthcare systems. Overall, maintaining a focus on enhancing efficacy and safety, while addressing accessibility and cost-effectiveness, will be crucial for stakeholders aiming to achieve long-term growth and impact in the cancer supportive care sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of cancer coupled with increase in the geriatric population
  • Increasing approval and launch of new products
  • Increase in R&D activities for development of cancer supportive care drugs
• Market Restraints
  • High cost of cancer supportive care drugs
• Market Opportunities
  • Development of novel targeted therapies for the treatment of cancer
  • Rising adoption of biosimilar and increasing government expenditure on healthcare
• Market Challenges
  • Side effects associated with consumption of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Supportive Care Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Supportive Care Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Supportive Care Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Supportive Care Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Supportive Care Drugs Market

A detailed market share analysis in the Cancer Supportive Care Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Supportive Care Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Supportive Care Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Supportive Care Drugs Market

A strategic analysis of the Cancer Supportive Care Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Supportive Care Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Supportive Care Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapeutic Class, market is studied across Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents, Granulocyte-Colony Stimulating Factors, Non-Steroidal Anti-Inflammatory Drugs, and Opioids.
• Based on Application, market is studied across Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer coupled with increase in the geriatric population
    • 5.1.1.2. Increasing approval and launch of new products
    • 5.1.1.3. Increase in R&D activities for development of cancer supportive care drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of cancer supportive care drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of novel targeted therapies for the treatment of cancer
    • 5.1.3.2. Rising adoption of biosimilar and increasing government expenditure on healthcare
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with consumption of drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Supportive Care Drugs Market, by Therapeutic Class

• 6.1. Introduction
• 6.2. Antiemetics
• 6.3. Bisphosphonates
• 6.4. Erythropoiesis Stimulating Agents
• 6.5. Granulocyte-Colony Stimulating Factors
• 6.6. Non-Steroidal Anti-Inflammatory Drugs
• 6.7. Opioids

7. Cancer Supportive Care Drugs Market, by Application

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Colorectal Cancer
• 7.4. Liver Cancer
• 7.5. Lung Cancer
• 7.6. Prostate Cancer
• 7.7. Stomach Cancer

8. Americas Cancer Supportive Care Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Cancer Supportive Care Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Cancer Supportive Care Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Acacia Pharma Group PLC
• 2. Amgen Inc.
• 3. Aphios Corporation
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. Celldex Therapeutics
• 7. GSK PLC
• 8. Helsinn Healthcare SA
• 9. Heron Pharma
• 10. Ipsen Pharma
• 11. Johnson & Johnson
• 12. Merck & Co.
• 13. Novartis International AG
• 14. Sanofi SA
• 15. Sun Pharmaceutical Industries Ltd.
• 16. Teva Pharmaceutical Industries Ltd.